                         SEQUENCE LISTING

<110>  Sanofi
       Esperet, Corinne
       Jagerschmidt, Alexandre
       Soubrane, Christina
       Subramaniam, Arun
 
<120>  Anti-IL4-IL13 Bispecific Antibodies

<130>  14-1111-WO

<150>  US 62/018,253
<151>  2014-06-27

<150>  EP 14306477.2
<151>  2014-09-24

<150>  US 62/102,097
<151>  2015-01-11

<150>  US 62/102,555
<151>  2015-01-12

<160>  7     

<170>  PatentIn version 3.5

<210>  1
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  humanized mouse/ mouse VL3 region

<400>  1

Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr 
            20                  25                  30          


Gly Gln Ser Tyr Met His Trp Tyr Gln Gln Lys Ala Gly Gln Pro Pro 
        35                  40                  45              


Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asp 
65                  70                  75                  80  


Pro Val Gln Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Asn Ala 
                85                  90                  95      


Glu Asp Ser Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110     


<210>  2
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  humanized mouse/mouse VH2 region

<400>  2

Glu Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Gly Gly 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asp Ser 
            20                  25                  30          


Ser Ile Asn Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Met Ile Trp Gly Asp Gly Arg Ile Asp Tyr Ala Asp Ala Leu Lys 
    50                  55                  60                  


Ser Arg Leu Ser Ile Ser Lys Asp Ser Ser Lys Ser Gln Val Phe Leu 
65                  70                  75                  80  


Glu Met Thr Ser Leu Arg Thr Asp Asp Thr Ala Thr Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Asp Gly Tyr Phe Pro Tyr Ala Met Asp Phe Trp Gly Gln Gly Thr 
            100                 105                 110         


Ser Val Thr Val Ser Ser 
        115             


<210>  3
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  humanized mouse/mouse VL1 region

<400>  3

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Val Ser Val Gly 
1               5                   10                  15      


Asp Thr Ile Thr Leu Thr Cys His Ala Ser Gln Asn Ile Asp Val Trp 
            20                  25                  30          


Leu Ser Trp Phe Gln Gln Lys Pro Gly Asn Ile Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Lys Ala Ser Asn Leu His Thr Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Ala His Ser Tyr Pro Phe 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 
            100                 105             


<210>  4
<211>  124
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  humanized mouse/mouse VH1 region

<400>  4

Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr 
            20                  25                  30          


Trp Ile His Trp Ile Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Met Ile Asp Pro Ser Asp Gly Glu Thr Arg Leu Asn Gln Arg Phe 
    50                  55                  60                  


Gln Gly Arg Ala Thr Leu Thr Val Asp Glu Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Arg Ser Pro Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Arg Leu Lys Glu Tyr Gly Asn Tyr Asp Ser Phe Tyr Phe Asp Val 
            100                 105                 110         


Trp Gly Ala Gly Thr Leu Val Thr Val Ser Ser Ala 
        115                 120                 


<210>  5
<211>  124
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  humanized mouse/mouse VH2 region

<400>  5

Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr 
            20                  25                  30          


Trp Ile His Trp Ile Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Met Ile Asp Ala Ser Asp Gly Glu Thr Arg Leu Asn Gln Arg Phe 
    50                  55                  60                  


Gln Gly Arg Ala Thr Leu Thr Val Asp Glu Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Arg Ser Pro Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Arg Leu Lys Glu Tyr Gly Asn Tyr Asp Ser Phe Tyr Phe Asp Val 
            100                 105                 110         


Trp Gly Ala Gly Thr Leu Val Thr Val Ser Ser Ala 
        115                 120                 


<210>  6
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  linker

<400>  6

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
1               5                   10  


<210>  7
<211>  30
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  primer

<400>  7
ggaggcggag ggtccggagg cggaggatcc                                        30


